Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...
MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for ...
Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for ...
Combined company expected to trade on Nasdaq under “KLRS” after closingPALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 ...
“We expect to receive 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in this quarter,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
Usha (name changed), 62, was experiencing sudden and painless loss of vision in the right eye for one day when she turned up ...
Kalaris Therapeutics, Inc. ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization ...
UNITY Biotechnology, Inc. ("UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. <li /> GLOW2 study design mirrors GLOW1 study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback